Pfizer Inc. (NYSE:PFE) is a global pharmaceutical company known for its innovative healthcare solutions. It develops and manufactures medicines and vaccines for a wide range of medical disciplines. Pfizer competes with other pharmaceutical giants like Johnson & Johnson and Merck. On October 10, 2025, Morgan Stanley set a price target of $32 for Pfizer, suggesting a potential increase of 26.78% from its current price of $25.24.
Pfizer's stock is positioned for a potential recovery, supported by recent corporate developments. The Trump administration's three-year reprieve on drug-import tariffs is a significant factor. This decision strengthens the bullish outlook for Pfizer, despite previous market reactions. The upcoming Q3 earnings report on November 4, 2025, is expected to provide insights into Pfizer's progress in oncology and the impact of the tariff decision.
Pfizer's agreement with TrumpRx, which includes offering drug discounts and committing $70 billion to U.S. manufacturing and research and development, reduces regulatory uncertainty. This strategic move is likely to attract new investors as the company meets its guidance. The current stock price of $25.24 reflects a decrease of 1.69%, with a drop of $0.43 today. The stock's price ranged from $25.21 to $25.90 during the trading day.
Over the past year, Pfizer's stock has reached a high of $29.82 and a low of $20.92. The company's market capitalization is approximately $143.5 billion. Today's trading volume for Pfizer is 40,998,544 shares on the New York Stock Exchange. These figures highlight the market's interest in Pfizer and its potential for growth, especially with the recent developments and strategic agreements in place.
